SeaStar Medical provides regulatory update regarding Selective Cytopheretic Device use in pediatric acute kidney injury under a Humanitarian Device Exemption
SeaStar Medical Holding Corporation announces receipt of a correspondence from the FDA Center for Biologics Evaluation and Research (CBER) indicating that the Agency considers the Selective Cytopheretic Device… read more.
